Corline Biomedical Past Earnings Performance
Past criteria checks 0/6
Corline Biomedical has been growing earnings at an average annual rate of 26%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 23.2% per year.
Key information
26.0%
Earnings growth rate
33.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | 23.2% |
| Return on equity | -11.4% |
| Net Margin | -40.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Aug 24
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth
Mar 15We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow
Nov 26Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Jun 22We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth
Feb 16Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth
Jun 14Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation
Feb 28Revenue & Expenses Breakdown
How Corline Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 24 | -10 | 28 | 0 |
| 30 Jun 24 | 29 | -6 | 30 | 0 |
| 31 Mar 24 | 31 | -4 | 28 | 0 |
| 31 Dec 23 | 36 | -2 | 29 | 0 |
| 30 Sep 23 | 37 | -1 | 29 | 0 |
| 30 Jun 23 | 40 | 1 | 27 | 0 |
| 31 Mar 23 | 38 | 4 | 24 | 0 |
| 31 Dec 22 | 33 | 2 | 21 | 0 |
| 30 Sep 22 | 31 | 1 | 19 | 0 |
| 30 Jun 22 | 23 | -3 | 17 | 0 |
| 31 Mar 22 | 19 | -6 | 17 | 0 |
| 31 Dec 21 | 17 | -7 | 16 | 0 |
| 30 Sep 21 | 15 | -6 | 15 | 0 |
| 30 Jun 21 | 13 | -6 | 15 | 0 |
| 31 Mar 21 | 14 | -6 | 16 | 0 |
| 31 Dec 20 | 15 | -7 | 18 | 0 |
| 30 Sep 20 | 14 | -9 | 18 | 0 |
| 30 Jun 20 | 14 | -9 | 18 | 0 |
| 31 Mar 20 | 14 | -9 | 17 | 0 |
| 31 Dec 19 | 12 | -10 | 17 | 0 |
| 30 Sep 19 | 11 | -9 | 16 | 0 |
| 30 Jun 19 | 11 | -9 | 15 | 0 |
| 31 Mar 19 | 10 | -8 | 15 | 0 |
| 31 Dec 18 | 10 | -7 | 13 | 0 |
| 30 Sep 18 | 17 | -7 | 16 | 0 |
| 30 Jun 18 | 16 | -6 | 17 | 0 |
| 31 Mar 18 | 15 | -7 | 17 | 0 |
| 31 Dec 17 | 16 | -8 | 19 | 0 |
| 30 Sep 17 | 7 | -8 | 16 | 0 |
| 30 Jun 17 | 9 | -8 | 15 | 0 |
| 31 Mar 17 | 10 | -6 | 14 | 0 |
| 31 Dec 16 | 9 | -5 | 14 | 0 |
| 30 Sep 16 | 8 | -6 | 13 | 0 |
| 30 Jun 16 | 7 | -6 | 12 | 0 |
| 31 Mar 16 | 5 | -7 | 11 | 0 |
| 31 Dec 15 | 4 | -6 | 9 | 0 |
| 31 Dec 14 | 4 | -3 | 6 | 0 |
| 31 Dec 13 | 4 | -2 | 7 | 0 |
Quality Earnings: CLBIO is currently unprofitable.
Growing Profit Margin: CLBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 26% per year.
Accelerating Growth: Unable to compare CLBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLBIO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).
Return on Equity
High ROE: CLBIO has a negative Return on Equity (-11.4%), as it is currently unprofitable.